323 related articles for article (PubMed ID: 22245704)
1. Metabolic effects of anti-angiogenic therapy in tumors.
Zulato E; Curtarello M; Nardo G; Indraccolo S
Biochimie; 2012 Apr; 94(4):925-31. PubMed ID: 22245704
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effects of antiangiogenic drugs in tumors: therapeutic implications.
Quintieri L; Selmy M; Indraccolo S
Biochem Pharmacol; 2014 May; 89(2):162-70. PubMed ID: 24607274
[TBL] [Abstract][Full Text] [Related]
3. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
4. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
[TBL] [Abstract][Full Text] [Related]
5. Limiting supply.
Nat Rev Cancer; 2008 Aug; 8(8):577. PubMed ID: 18672479
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
Ferrara N; Hillan KJ; Novotny W
Biochem Biophys Res Commun; 2005 Jul; 333(2):328-35. PubMed ID: 15961063
[TBL] [Abstract][Full Text] [Related]
7. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
8. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
9. Is VEGF a predictive biomarker to anti-angiogenic therapy?
Otrock ZK; Hatoum HA; Musallam KM; Awada AH; Shamseddine AI
Crit Rev Oncol Hematol; 2011 Aug; 79(2):103-11. PubMed ID: 20724177
[TBL] [Abstract][Full Text] [Related]
10. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ
Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.
Mitchell DC; Bryan BA
J Cell Biochem; 2010 Oct; 111(3):543-53. PubMed ID: 20626031
[TBL] [Abstract][Full Text] [Related]
12. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
13. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
De Bock K; Cauwenberghs S; Carmeliet P
Curr Opin Genet Dev; 2011 Feb; 21(1):73-9. PubMed ID: 21106363
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenesis in cancer therapy: Hercules and hydra.
Bellou S; Pentheroudakis G; Murphy C; Fotsis T
Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
[TBL] [Abstract][Full Text] [Related]
15. Vascular normalization: study examines how antiangiogenesis therapies work.
Webb T
J Natl Cancer Inst; 2005 Mar; 97(5):336-7. PubMed ID: 15741568
[No Abstract] [Full Text] [Related]
16. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
17. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies.
Ellis LM; Rosen L; Gordon MS
Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372
[TBL] [Abstract][Full Text] [Related]
18. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
19. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
Sato Y
Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
[TBL] [Abstract][Full Text] [Related]
20. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
